<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Betamethasone (topical): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Betamethasone (topical): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Betamethasone (topical): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="94961" href="/d/html/94961.html" rel="external">see "Betamethasone (topical): Drug information"</a> and <a class="drug drug_patient" data-topicid="95151" href="/d/html/95151.html" rel="external">see "Betamethasone (topical): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F23780933"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Diprolene;</li>
<li>Diprolene AF [DSC];</li>
<li>Luxiq [DSC];</li>
<li>Sernivo</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871722"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Betaderm;</li>
<li>Beteflam;</li>
<li>Celestoderm V [DSC];</li>
<li>Celestoderm V/2 [DSC];</li>
<li>Diprolene;</li>
<li>Diprosone;</li>
<li>TARO-Sone;</li>
<li>TEVA-Ectosone;</li>
<li>TEVA-Topilene;</li>
<li>TEVA-Topisone;</li>
<li>Valisone Scalp [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F24168324"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Corticosteroid, Topical</span></li></ul></div>
<div class="block dop drugH1Div" id="F23780968"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosage should be based on severity of disease and patient response; use smallest amount for shortest period of time to avoid HPA axis suppression. Therapy should be discontinued when control is achieved.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="db00c349-e8c7-4629-a65f-c9656671bb40">Dermatoses</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatoses (corticosteroid-responsive):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Betamethasone valerate:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Cream 0.1%, ointment 0.1%: Children and Adolescents: Topical: Apply a thin film to the affected area once to 3 times daily; usually once- or twice-daily application is effective.</p>
<p style="text-indent:-2em;margin-left:6em;">Lotion 0.1%: Children and Adolescents: Topical: Apply a few drops to the affected area twice daily in the morning and at night; in some cases, more frequent application may be necessary; following improvement reduce to once-daily application.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Betamethasone dipropionate (<span style="text-decoration: underline">un</span>augmented formulation): </i></p>
<p style="text-indent:-2em;margin-left:6em;">Cream 0.05%, ointment 0.05%: Adolescents: Topical: Apply a thin film to affected area once daily; in some cases, twice-daily dosing may be necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Lotion 0.05%: Adolescents: Topical: Apply a few drops to the affected area twice daily, in the morning and night; rub in gently until it disappears.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Betamethasone dipropionate (augmented formulation): </i></p>
<p style="text-indent:-2em;margin-left:6em;">Cream 0.05%, ointment 0.05%: Adolescents: Topical: Apply a thin film to affected area once or twice daily; maximum dose: 50 g/week; evaluate continuation of therapy if no improvement within 2 weeks of treatment.</p>
<p style="text-indent:-2em;margin-left:6em;">Gel 0.05%: Children ≥12 years and Adolescents: Topical: Apply a thin layer to the affected area once or twice daily; rub in gently; maximum dose: 50 g/week; not recommended for use longer than 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Lotion 0.05%: Adolescents: Topical: Apply a few drops to the affected area once or twice daily; rub in gently; maximum dose: 50 <b>mL</b>/week; not recommended for use for longer than 2 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="104864b1-f0bc-43ed-b21a-8a6777960599">Psoriasis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriasis (plaque), treatment: </b>Adolescents ≥18 years of age: <i>Betamethasone dipropionate spray 0.05%</i>: Topical: Apply spray to affected area twice daily and rub in gently for up to 4 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51073525"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51073526"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F23780969"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="94961" href="/d/html/94961.html" rel="external">see "Betamethasone (topical): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Base dosage on severity of disease and patient response. Use lowest dose possible for shortest period of time to avoid HPA axis suppression. Therapy should be discontinued when control is achieved.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7fcdd7c2-fcea-459c-b474-e68d6e2cb01d">Corticosteroid-responsive dermatoses</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Corticosteroid-responsive dermatoses:</b>
<b>Topical:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Cream, augmented formulation: Betamethasone dipropionate 0.05%: Apply once or twice daily (maximum: 50 g weekly).</p>
<p style="text-indent:-2em;margin-left:4em;">Cream, unaugmented formulation:</p>
<p style="text-indent:-2em;margin-left:6em;">Betamethasone dipropionate 0.05%: Apply once daily; may increase to twice daily if needed</p>
<p style="text-indent:-2em;margin-left:6em;">Betamethasone valerate 0.1%: Apply 1 to 3 times daily. <b>Note: </b> Once- or twice-daily applications are usually effective.</p>
<p style="text-indent:-2em;margin-left:4em;">Foam: Apply to the scalp twice daily, once in the morning and once at night. <b>Note:</b> Reassess if no improvement after 2 weeks of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Gel, augmented formulation: Apply once or twice daily (maximum: 50 g weekly). <b>Note:</b> Reassess if no improvement after 2 weeks of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Lotion, augmented formulation: Betamethasone dipropionate 0.05%: Apply a few drops once or twice daily (maximum: 50 mL weekly). <b>Note:</b> Reassess if no improvement after 2 weeks of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Lotion, unaugmented formulation:</p>
<p style="text-indent:-2em;margin-left:6em;">Betamethasone dipropionate 0.05%: Apply a few drops twice daily</p>
<p style="text-indent:-2em;margin-left:6em;">Betamethasone valerate 0.1%: Apply a few drops twice daily; may consider increasing dose for resistant cases. Following improvement, may apply once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Ointment, augmented formulation: Betamethasone dipropionate 0.05%: Apply once or twice daily (maximum: 50 g weekly). <b>Note:</b> Reassess if no improvement after 2 weeks of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Ointment, unaugmented formulation:</p>
<p style="text-indent:-2em;margin-left:6em;">Betamethasone dipropionate 0.05%: Apply once daily; may increase to twice daily if needed</p>
<p style="text-indent:-2em;margin-left:6em;">Betamethasone valerate 0.1%: Apply 1 to 3 times daily. <b>Note:</b> Once- or twice-daily applications are usually effective.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4fb8c5f3-a1b3-4ba3-b517-cc8663ef3c7c">Plaque psoriasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plaque psoriasis:</b>
<b>Topical:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Patch [Canadian product]: Betamethasone valerate: Apply 1 patch (2.25 mg) to each affected area once daily [up to 5 patches (11.25 mg) may be applied daily]; maximum duration of therapy: 30 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Spray, unaugmented formulation: Betamethasone dipropionate 0.05%: Apply twice daily for up to 4 weeks</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990877"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988170"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F23780952"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Local: Application-site reaction (includes application-site atrophy, application-site burning, application-site irritation, application-site pain, application-site pruritus, stinging of the skin)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, alopecia, pruritus (≤2%), xeroderma (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis, erythema of skin, folliculitis, skin discoloration, skin rash, telangiectasia</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Localized vesiculation</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acneiform eruption, allergic contact dermatitis, atrophic striae, hypertrichosis, hypopigmentation, maceration of the skin, miliaria, perioral dermatitis, skin atrophy, skin tightness (including cracking)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: HPA axis suppression</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Secondary infection</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cataract, glaucoma, increased intraocular pressure, retinopathy (central serous chorioretinopathy)</p></div>
<div class="block coi drugH1Div" id="F23780949"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to betamethasone, other corticosteroids, or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">Spray: There are no contraindications listed in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Treatment of rosacea, acne vulgaris, perioral dermatitis, or pruritus without inflammation (foam); viral diseases (eg, herpes simplex, chicken pox, vaccina); untreated bacterial, fungal, parasitic, syphilis, and tubercular infection involving the skin; eruptions following vaccinations (patch); application to eyes (foam); &lt;18 years of age (patch). <b>Note:</b> Product labels may vary (refer also to product labels).</p></div>
<div class="block war drugH1Div" id="F23780950"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Contact dermatitis: Allergic contact dermatitis can occur and is usually diagnosed by failure to heal rather than clinical exacerbation; discontinue use if irritation occurs and treat appropriately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to varicella zoster (chickenpox) should be avoided; corticosteroids should not be used to treat ocular herpes simplex.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: Topical corticosteroids, including betamethasone, may increase the risk of posterior subcapsular cataracts and glaucoma. Monitor for ocular symptoms. Avoid contact with eyes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin reactions: Discontinue if skin irritation or contact dermatitis occurs; do not use in patients with decreased skin circulation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing syndrome (rare), hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, application to large surface areas, or prolonged use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Use of augmented formulations in patients &lt;13 years of age is not recommended. For all formulations, children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients. Use lowest dose possible for shortest period of time to avoid HPA axis suppression.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For topical use only; avoid contact with eyes. Not for oral, ophthalmic, or intravaginal use. Do not use occlusive dressings on weeping or exudative lesions and general caution with occlusive dressings should be observed; adverse effects may be increased. In the presence of a fungal or bacterial dermatologic infection, institute appropriate antifungal or antibacterial therapy. If the infection does not resolve promptly, discontinue use until the infection has been adequately controlled.</p>
<p style="text-indent:-2em;margin-left:4em;">• Augmented (eg, very high potency) products: Use of augmented formulations in patients &lt;13 years of age is not recommended. Not for treatment of rosacea, perioral dermatitis, or if skin atrophy is present at treatment site; not for facial, groin, axillary, oral, ophthalmic, or intravaginal use; not for use in a diapered area. Avoid concurrent use of other corticosteroids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Flammable contents: Foam contains flammable propellants. Avoid fire, flame and smoking during and immediately following administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patch [Canadian product]: Has not been studied in psoriasis of the face, scalp or intertriginous areas; contains methyl and propyl parahydroxybenzoate, which may cause hypersensitivity (sometimes delayed).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Withdraw therapy with gradual tapering of dose by reducing the frequency of application or substitution of a less potent steroid.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878793"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">The extent of percutaneous absorption is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, age of the patient, prolonged duration of use, and the use of occlusive dressings. Percutaneous absorption of topical steroids is increased in neonates (especially preterm neonates), infants, and young children. Infants and small children may be more susceptible to HPA axis suppression, intracranial hypertension, Cushing syndrome, or other systemic toxicities due to larger skin surface area to body mass ratio. HPA axis suppression was observed in 32% of infants and children (age range: 3 months to 12 years) being treated with betamethasone dipropionate cream (0.05%) for atopic dermatitis in an open-label trial (n=60); the incidence was greater younger patients vs older children (mean reported incidence for age ranges: ≤1 year: 50%; 2 to 8 years: 32% to 38%; 9 to 12 years: 17%). </p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F23780990"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External, as dipropionate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (15 g, 45 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External, as dipropionate augmented [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diprolene AF: 0.05% (15 g [DSC], 50 g [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (15 g, 50 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External, as valerate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1% (15 g, 45 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Emulsion, External, as dipropionate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sernivo: 0.05% (120 mL) [contains cetostearyl alcohol, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Foam, External, as valerate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Luxiq: 0.12% (50 g [DSC], 100 g [DSC]) [cfc free; contains alcohol, usp, cetyl alcohol, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.12% (50 g, 100 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, External, as dipropionate augmented [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (15 g, 50 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Lotion, External, as dipropionate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (60 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Lotion, External, as dipropionate augmented [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (30 mL, 60 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Lotion, External, as valerate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1% (60 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External, as dipropionate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (15 g, 45 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External, as dipropionate augmented [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diprolene: 0.05% (15 g [DSC], 50 g [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diprolene: 0.05% (15 g, 50 g) [contains propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (15 g, 45 g, 50 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External, as valerate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1% (15 g, 45 g)</p></div>
<div class="block geq drugH1Div" id="F23780936"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F23780992"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Betamethasone Dipropionate Aug External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $0.31 - $5.58</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Betamethasone Dipropionate External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $2.77 - $3.52</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Betamethasone Valerate External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $1.49 - $1.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Emulsion</b> (Sernivo External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per mL): $10.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Foam</b> (Betamethasone Valerate External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.12% (per gram): $6.54</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Betamethasone Dipropionate Aug External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $4.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Lotion</b> (Betamethasone Dipropionate Aug External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per mL): $2.50 - $3.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Lotion</b> (Betamethasone Dipropionate External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per mL): $0.75 - $0.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Lotion</b> (Betamethasone Valerate External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per mL): $1.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Betamethasone Dipropionate Aug External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $4.23 - $5.55</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Betamethasone Dipropionate External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $3.14 - $4.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Betamethasone Valerate External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $1.36 - $1.39</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Diprolene External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $8.32</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871723"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Betaderm: 0.05% (15 g, 454 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Celestoderm V/2: 0.05% ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (450 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External, as dipropionate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diprosone: 0.05% (15 g, 50 g) [contains cetyl alcohol, chlorocresol (chloro-m-cresol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TARO-Sone: 0.05% (15 g, 50 g, 450 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (15 g, 50 g, 450 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External, as dipropionate augmented [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (15 g, 50 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External, as valerate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Betaderm: 0.1% (15 g, 454 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Celestoderm V: 0.1% ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1% (15 g, 450 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Lotion, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (60 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Lotion, External, as dipropionate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diprosone: 0.05% (75 mL) [contains isopropyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TARO-Sone: 0.05% ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (30 mL, 75 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Lotion, External, as dipropionate augmented [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (30 mL, 60 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Lotion, External, as valerate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Betaderm: 0.1% (30 mL, 75 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valisone Scalp: 0.1% ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1% (30 mL, 60 mL, 75 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Betaderm: 0.05% (15 g, 454 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Celestoderm V/2: 0.05% ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External, as dipropionate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diprosone: 0.05% (15 g, 50 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (15 g, 50 g, 450 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External, as dipropionate augmented [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diprolene: 0.05% (50 g) [contains propylene glycol, propylene glycol stearate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (15 g, 50 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External, as valerate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Betaderm: 0.1% (15 g, 454 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Celestoderm V: 0.1% ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch 24 Hour, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Beteflam: 2.25 mg (4 ea, 8 ea, 16 ea) [contains edetate (edta) disodium, methylparaben, propylparaben]</p></div>
<div class="block adip drugH1Div" id="F53570511"><span class="drugH1">Additional Information</span>
<p style="text-indent:-2em;margin-left:2em;">Very high potency (super high potency): Augmented betamethasone dipropionate ointment, lotion, gel </p>
<p style="text-indent:-2em;margin-left:2em;">High potency: Augmented betamethasone dipropionate cream, betamethasone dipropionate cream and ointment </p>
<p style="text-indent:-2em;margin-left:2em;">Intermediate potency: Betamethasone dipropionate lotion, betamethasone valerate cream </p></div>
<div class="block admp drugH1Div" id="F52614557"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Topical: For external use only. Apply sparingly to affected areas. Not for use on broken skin or in areas of infection. Do not apply to wet skin unless directed; do not cover with occlusive dressing unless directed. Do not apply very high potency agents to face, groin, axillae, or diaper area; avoid contact with eyes. Not for oral, ophthalmic, or intravaginal use. Wash hands after use.</p>
<p style="text-indent:-2em;margin-left:2em;">Betamethasone dipropionate spray: Spray directly onto affected areas (spray only enough to sufficiently cover the area); rub in gently. Shake well before use. Do not use if atrophy is present at the treatment site. Avoid use on the face, scalp, axilla, groin, or other intertriginous areas.</p>
<p style="text-indent:-2em;margin-left:2em;">Lotion: Shake well prior to use. Massage gently until lotion disappears.</p></div>
<div class="block adm drugH1Div" id="F23780975"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;">
<b>Topical:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Cream, ointment: Apply topical sparingly to affected areas. Do not use if atrophy is present at the treatment site. Do not cover with occlusive dressing unless directed otherwise by health care provider. Do not apply very high potency agents to face, groin, axillae, or diaper area. Not for oral, ophthalmic, or intravaginal use. Wash hands after use.</p>
<p style="text-indent:-2em;margin-left:2em;">Gel: Apply thin layer to affected area and rub in gently and completely. Do not cover affected area with occlusive dressing. Not for ophthalmic use. Avoid getting into eyes.</p>
<p style="text-indent:-2em;margin-left:2em;">Lotion: Apply topical sparingly to affected areas. Massage in gently until lotion disappears. Do not use if atrophy is present at the treatment site. Do not cover with occlusive dressing unless directed otherwise by health care provider. Do not apply very high potency agents to face, groin, axillae, or diaper area. Not for oral, ophthalmic, or intravaginal use. Wash hands after use.</p>
<p style="text-indent:-2em;margin-left:2em;">Foam: Invert can and dispense a small amount onto a saucer or other cool surface. Do not dispense directly into hands. Pick up small amounts of foam and gently massage into affected areas until foam disappears. Repeat until entire affected scalp area is treated. Do not cover with occlusive dressing unless directed otherwise by health care provider. Not for ophthalmic use. Avoid getting into eyes.</p>
<p style="text-indent:-2em;margin-left:2em;">Patch [Canadian product]: Clean and dry area to be treated prior to each application. May cut patch to size to cover lesion. Peel off protective film and apply adhesive medicated side to affected area; patch should be worn for 20 to 24 hours. After removing patch wait at least 30 minutes before applying a new one. Keep dry; if patch becomes wet, remove and wait until next scheduled dose before applying a new one. Do not cover with occlusive dressing. Patch should not be reused if it comes off; if edges of patch start to lift, apply medical adhesive tape to detached part only.</p>
<p style="text-indent:-2em;margin-left:2em;">Spray: Spray directly onto affected areas (spray only enough to sufficiently cover the area); rub in gently and wash hands after applying. Shake well before use. Do not use if atrophy is present at the treatment site. Do not cover with occlusive dressing unless directed otherwise by health care provider. For topical use only; not for oral, ophthalmic or vaginal use; avoid use on the face, scalp, axilla, groin, or other intertriginous areas.</p></div>
<div class="block sts drugH1Div" id="F25090737"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Cream, lotion, ointment, spray: Store at 15°C to 30°C (59°F to 86°F). Discard any unused spray after 4 weeks.</p>
<p style="text-indent:-2em;margin-left:2em;">Foam: Store at 20°C to 25°C (68°F to 77°F). Avoid fire, flame, or smoking during use. Do not puncture or incinerate container. Do not expose to heat or store at temperatures above 49°C (120°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Patch [Canadian product]: Store at 15°C to 25°C (59°F to 77°F). Use immediately after opening sachet.</p></div>
<div class="block usep drugH1Div" id="F53571133"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Betamethasone valerate:</p>
<p style="text-indent:-2em;margin-left:4em;">Cream, lotion, and ointment (0.1%): Treatment of inflammation and pruritus associated with corticosteroid-responsive dermatoses of the skin (FDA approved in pediatric patients [age not specified] and adults).</p>
<p style="text-indent:-2em;margin-left:4em;">Foam (0.12%): Treatment of inflammation and pruritus associated with corticosteroid-responsive dermatoses of the scalp including psoriasis (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Betamethasone dipropionate cream, lotion, and ointment (0.05%): Treatment of inflammation and pruritus associated with corticosteroid-responsive dermatoses of the skin (FDA approved in ages ≥13 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Betamethasone dipropionate spray (0.05%): Treatment of mild to moderate plaque psoriasis (FDA approved in ages ≥18 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Betamethasone dipropionate augmented cream, lotion, ointment, and gel (0.05%): Treatment of inflammation and pruritus associated with corticosteroid-responsive dermatoses of the skin (Cream, lotion, and ointment: FDA approved in ages ≥13 years and adults; Gel: FDA approved in ages ≥12 years and adults).</p></div>
<div class="block mst drugH1Div" id="F23780928"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Luxiq may be confused with Lasix</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Medium, high, and very high potency topical corticosteroids, when used in neonates and infants &lt;1 year of age for diaper dermatitis, are identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list; use should be avoided due to risk of adrenal suppression; systemic absorption is higher in pediatric patients than adults (strong recommendation; low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F23781009"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F23781008"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Betamethasone (Topical).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Corticosteroids (Topical).<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56165658"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Topical corticosteroids may be used for the treatment of corticosteroid-responsive dermatosis, such as atopic dermatitis, in patients planning a pregnancy (Vestergaard 2019).</p></div>
<div class="block pri drugH1Div" id="F23780946"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Systemic bioavailability of topical corticosteroids is variable (eg, integrity of skin, use of occlusion) and may be further influenced by trimester of pregnancy (Chi 2017). In general, the use of topical corticosteroids is not associated with a significant risk of adverse pregnancy outcomes. However, there may be an increased risk of low birth weight infants following maternal use of potent or very potent topical products, especially in high doses, although this risk is likely to be low (Andersson 2021; Chi 2015; Chi 2017).</p>
<p style="text-indent:0em;margin-top:2em;">When first-line treatments, such as emollients, are insufficient, topical corticosteroids may be used for the treatment of atopic dermatitis in pregnant patients (Vestergaard 2019). Topical corticosteroids are classified by potency; the medication and formulation (eg, cream, gel, and/or salt form) contribute to the potency classification (Oakley 2021; Stacey 2021; Tadicherla 2009). In general, use of the least potent product in limited amounts is recommended during pregnancy. Mild to moderate potency corticosteroids are preferred; potent to very potent topical corticosteroids should only be used as alternative therapy in limited amounts under obstetrical care. Pregnant patients should avoid application of topical corticosteroids to areas with high percutaneous absorption (eg, armpit, skin folds, vulva) (Chi 2017), and caution should be used when applying to areas prone to striae formation (eg, abdomen, breast, thighs) (Vestergaard 2019).</p></div>
<div class="block mopp drugH1Div" id="F53571132"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Growth; assess hypothalamic pituitary adrenal axis suppression (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test), ocular symptoms/visual disturbances.</p></div>
<div class="block pha drugH1Div" id="F23780956"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A<sub>2</sub> inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid. Betamethasone has intermediate to very high range potency (dosage-form dependent).</p></div>
<div class="block phk drugH1Div" id="F23780958"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Topical corticosteroids are absorbed percutaneously. The extent of absorption is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, age of the patient, prolonged duration of use, and the use of occlusive dressings. Percutaneous absorption of topical steroids is increased in neonates (especially preterm neonates), infants, and young children.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine and bile</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F24799714"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Betaderm | Betasone | Betaval | Betnovate | Celestoderm v | Celestone | Diprolene | Diprosone | Uticort</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Adenil b | Bactisona | Betacort | Betamat | Betametasona | Betametasona ahimsa | Betametasona biocrom | Betametasona lafedar | Betametasona Richet | Betasone g | Betatopic | Betnovate | Blacor | Butasona | Celestone | Cevicort | Coid | Corteroid | Corticas | Cortiderma | Denvercort | Dermizol | Diprocel | Diprosone | Maxisona | Metabulgin | Novocort | Quiacort | Transderma b | Valederm | Vitacortil B</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Betnovate | Diproderm | Diproforte</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Antroquoril | Betnovate | Celestone m | Cortival | Diprosone | Eleuphrat</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Bantovet | Bet a | Betameson | Betaval | Betnova | Betnovate | Diprosal | Metavet | Mexiderm | Sinacort</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Betnelan | Celestone | Diprolene | Diprosone | Topik</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Betneval | Dermosone | Diprolene | Diprosone</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Betaval | Betazon | Betnovate | Celestoderm v | Celestone | Diprosone</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Benevat | Betaderm | Betametagen | Betnolon | Betnovate | Betrat b | Betsona | Celestone | Cortifar | Dermovat | Dipropionato de Betametasona | Diprosone | Valbet | Valerato de Betametasona</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Betamethason Wolff | Betnovate | Celestone | Diprolen | Diprosone</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Betamed | Betneval | Dermia d</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Androcort | Betametasona | Betnovate | Cidoten-v | Cremirit | Diprolene | Diprosona | Diprospan | Disopranil | Esancort | Konicortil | Labosona | Pielun</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bei song | Di an song</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Alekot | Bacgen | Beta xonas | Betacrem | Betaderm t | Betadip | Betamet | Betametasona | Betametasona mk | Betnovate | Celestoderm | Celestone | Cortimicina | Dermaler | Diprocel | Diprosone | Fuciclear | Inflacor | Leuven | Tudermifar</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Beloderm | Betnovate | Celestoderm v | Diprosone | Kuterid</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aldosin | Bemon | Beta | Betacreme | Betadoc | Betagalen | Betamethadoc | Betamethason Wolff | Betnesalic | Betnesol v | Celestan v | Cordes beta | Deflatop | Diprosis | Diprosone | Linolacort Beta | Pentacort | Soderm</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Betoid | Diproderm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Betacort | Betaderm | Betametasona | Betametasona inmenol | Betaval | Celestoderm v | Celestone | Diprosone | Diprosone VO | Nobetzona</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Betametasona | Betapluss | Betnovate | Celestone | Diprocel | Nobetzona</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Betacorten | Betnovate | Celestoderm | Celestoderm v | Diprolen | Diproson</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Betaderm | Betamethasone | Betnovate | Celestone | Diprosone | Gedovete</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Celecrem | Celestoderm v | Celestone | Diproderm</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Beprosone | Betametasone | Betamethasone | Betamethasone dipropionate cream | Betamethasone Valerate Cream BP | Cortiderm</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Bemetson | Betnovat | Betoid-fatty | Celestoderm | Diproderm | Diprolen</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Betamethasone biogaran | Betneval | Celestoderm | Celestoderm relais | Diprolene | Diprosone</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Audavate | Bebate | Betacap | Betamethasone | Betamethasone kent | Betnovate | Diprosone</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Alo Haar | Betamatic | Betnovate | Celestoderm v | Celestone | Galinocort | Helpoderm | Locason | Movithiol | Osmoran | Propioform | Sanorvil</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Axcel Betamethason | Benosone | Betacort | Betaderm | Betaderm v | Betaderma | Betapion | Betasone | Betazone | Betcortderm | Betnovate | Betopic | Celestone | Derzid | Diprocel | Diprosone | Helpoderm | Prosone | Synmethasone | Uniflex</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Beloderm | Betazon</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Alphacort | Benoson | Betamethasone | Betason | Betnovate | Betopic | Celestoderm v | Celestone | Corsaderm | Diprosone-ov | Mesonta | Metonate | Molason | Orsaderm | Oviskin | Oviskin c | Proson | Protocort | Scanderma | Skizone | Vason</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Audavate | Betacap | Betnovate | Diprosone</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Betacorten | Betnovate | Dicorten | Diprolene | Diprosone</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bet | Betaderm | Betadip | Betagel | Betamethasone | Betamil | Betatopic | Betnovate | Bevalerate | Celestone | Cortiderm | Dip | Diplene | Diprovate | Diprovate-rd | Exevate | Lupiderm | Propynate | Provate | Sternon | Topicasone | Ultravate | Walacort</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">As betnosun | Betacon | Betasone | Betnasum d | Betnosadain | Betnosam | Betnoyat</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Beben | Beta 21 | Betamesol | Betametasone Dipropionato | Celestoderm v | Celestone | Diprosone | Ecoval | Flogoderm</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Betaval | Betnovate | Betopic | Bitnoval | Celestone | Dermesone | Diprosone | Valederm | Vasone</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Anflavate | Antebate | Asakin mikasa | Asakin towa | Asdeloson | Betaclin | Betamamallet | Betnevate | Caramila dp | Cordel | Dabbeta | Dermitt | Dermosol | Dermosol dp | Diprocel sato | Dp pollon | Floderm | Hizubot | Hormezon | Ijilone dp | Keligroll | Keligroll mayado | Keligroll merck hoei | Muhibeta v alfresa | Nolcot | Rinderon dp | Rinderon v | Rinderon vs | Salex</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Bentopic | Betaderm | Betason | Betcosyl | Betnovate | Betpharm | Dawavate | Dermosone | Diprosone | Elyvate | Laeovate | Maxobeta | Mediven | Netasole | Tasone | Unibet</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Celestone | Dermason</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Betaderm | Betnovate | Diprolene | Diprosone</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Betasone | Betaval | Betnovate | Celestone | Diprosone</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Beloderm | Bemon | Betnovate | Celestoderm v | Kuterid</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Betnelan | Celestan v | Celestone | Diprosone | Topik</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Beloderm | Betacorten | Betnovate | Celestoderm | Celestoderm v | Celestone | Diprolen | Diprosone | Kuterid</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Betneval | Dermosone | Diprolene | Diprosone | Skinosone</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bemetasin | Betametasona | Betnovate | Celestoderm v | Celestone | Dermoval | Diprosone | Sonblefam's</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Axcel betamethasone | Beavate | Benosone | Beprosone | Besone | Beta | Betaderma | Betamethasone | Betapro | Betasolve | Betasone | Betaval | Betnosone | Betnovate | Bevarate | Camnovate | Celestoderm v | Celestone | Cortivate | Dermasole | Dermasole DP | Diprobet | Diproderma | Diprosone | Dipvite skin | Dynavate | Setrosone | Uniflex | Uniqler</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Betamethason | Betamethason Gf | Betamethason ratiopharm | Betamethason sandoz | Betnelan | Celestoderm | Celestone | Diprolene | Diprosone</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Betagalen | Betnovat | Betnovate | Betoid</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Beta | Beta scalp | Betnovate | Celestone | Diprosone</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Betacort | Betacrem | Betaflam | Betametasona | Betapluss | Betaquilab | Betnovate | Canalven | Celestone | Cortimax | Cortixyl | Diproderm | Diprosone | Medibeta | Topiderm | Ultrason</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Beprosone | Beta | Betacin | Betacrem | Betaderm | Betapplied | Betnasone | Betnoderm | Betnovate | Celestone | Diprolene | Diprosone | Innodesone | Lornasone | Metsobet | Ritemed betamethasone dipropionate | S Met | Steroderm | Valezone</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Beason | Betacin | Betaderm | Betadip | Betakin lotion | Betamet | Betanate | Betanoor | Betasol | Betaval | Betnocin | Betnopharm | Betnovate | Betonil | Danovate N | Dimed | Dioderm | Diprocort | Diprolene | Diprosan | Effidex | Encore | Glovat | Junate | Ketnorin | Pro-one | Provate | Valisone</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Beloderm | Betnovate | Celestoderm | Celestoderm v | Diprolene | Diprosone | Kuterid</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Alphatrex | Benisone | Beta-val | Betameth dipropionate | Betamethasone dipropionate augmented | Betamethasone Diproprionate | Betatrex | Celestone | Del-Beta | Diprolene | Diprolene AF | Diprosone | Maxivate</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Betnovate | Betnovate Capilar | Celestone | Cilestoderme | Dibetop | Diprosone | Diprosone n.v. | Vabeta</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Alercrom | Bacort | Betaderm | Betametasona mintlab | Betametasona promepar | Betasona | Betnovate | Clobecort | Crinex | Dexacort | Diprosone | Fienil | Hexoderm | Megacort | Ultrason</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Betaderm | Betamed | Betamet | Betasone | Betaval | Betnovate | Betnovate Scalp Application | Bevason | Diprolene | Diprosone | Riavate</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Beloderm | Betaderm | Betametazona fiterman | Betasone | Betnovate | Celestoderm v | Dicorten | Ekarzin | Helpoderm</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Akriderm | Beloderm | Betamethasone | Betliben | Betnovate | Celestoderm v | Celestone | Valoderm</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Betaderm | Betamed | Betasone | Betaval | Betnovate | Celestoderm v | Celestone | Diprolene | Diprosone | Riavate | Tabeta</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Betnoderm | Betnovat | Betoid | Celeston valerat | Diproderm | Diprolen</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Axcel betamethasone | Beprosone | Besone | Betacorten | Betalone | Betamethasone | Betasone | Betnovate | Betopic | Camnovate | Celestoderm v | Celestone | Dermasone | Diprocel | Diproderma | Diprosone | Medobeta | Synmethasone | Temprosone | Uniflex</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Beloderm | Diprosone | Flosteron | Kuterid</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Beloderm | Betnovate | Celestoderm v | Diprosone | Kuterid</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Betnovate</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Bennasone | Benocort | Beprogel | Bepronate | Beprosone | Berate | Besone | Bessasone | Bet Star | Beta | Betacort | Betaderm | Betama | Betamet | Betameth | Betamethasone | Betanate | Betapro | Betasone | Betatone | Bethasone | Betnovate | Betosone | Bevelar | Bipro | Celestoderm v | Celestone | Clinivate | Coxavate-d | Derma | Dertima | Derzid | Diprobet | Diprosone | Hoe beprosone | Pipbesone | Polynovate | Pronavate | Sanobet | T.m.bet | Topaben | Valbet | Valerbet</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Betasone | Betaval | Betneval | Celasone | Dermosone | Dimetasone | Diprosone | Suprasone | Valecort</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Betnovate | Celestoderm v | Celestone | Dermabel | Dermakort | Diprolene | Novovate</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Badine | Batasone | Beben | Beca-a | Benison | Besong | Beta | Betason | Betasone | Betnovate | Betopic | Celestone | Ciprosone | Diprosone | Kingderon | Lanbason | Parmason | Peijisone | Persivate | Promisone | Propisone | Rinderon v | Septon | Shinshin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Beloderm | Betabel | Betaderm | Betamethasone | Betazone | Celestoderm | Celestone | Kuterid | Mezoderm | Soderm</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Agovate | Axcel betamethasone | Betad | Betaderm | Betaderm ointment | Betasol | Betnovate | Elyvate | Laeovate | Mediven</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Betametasona | Betnovate | Cortipyren | Diprocel | Diprosone | Dosbe</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Betacort | Betaderm | Betamer | Betametasona | Betnovate | Celestoderm | Diprocel | Diprosone | Itisona</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Hemprenol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco betamethasone | Adco-betamethasone | Betnesol | Betnovate | Celestoderm v | Diprolene | Diprosone | Lenovate | Micro betamethasone | Persivate | Repivate | Topivate | Vari betamethasone</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Beprosone | Betamil | Betasone | Betnovate | Cobet | Diproson | Dipvite skin | Elyvate | Unibet | Valizyg</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Adco betamethasone | Axcel betamethasone | Betasone | Novaderm</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-topical-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33950165">
<a name="33950165"></a>Andersson NW, Skov L, Andersen JT. Evaluation of topical corticosteroid use in pregnancy and risk of newborns being small for gestational age and having low birth weight. <i>JAMA Dermatol</i>. 2021;157(7):788-795. doi:10.1001/jamadermatol.2021.1090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-topical-pediatric-drug-information/abstract-text/33950165/pubmed" id="33950165" target="_blank">33950165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GWLabs.1">
<a name="GWLabs.1"></a>Betamethasone dipropionate cream, lotion, ointment [prescribing information]. South Plainfield, NJ: G &amp; W Laboratories; January 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Solubiomix.1">
<a name="Solubiomix.1"></a>Betamethasone dipropionate gel [prescribing information]. Madisonville, LA: Solubiomix LLC; September 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Actavis.1">
<a name="Actavis.1"></a>Betamethasone dipropionate cream [prescribing information]. Parsippany, NJ: Actavis Pharma, Inc; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Padagis.1">
<a name="Padagis.1"></a>Betamethasone dipropionate ointment [prescribing information]. Allegan, MI: Padagis; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perrigo.1">
<a name="Perrigo.1"></a>Betamethasone dipropionate lotion, USP [prescribing information]. Allegan, MI: Padagis; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fougera.1">
<a name="Fougera.1"></a>Betamethasone valerate cream, lotion, ointment [prescribing information]. Melville, NY: Fougera; July 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Actavis.2">
<a name="Actavis.2"></a>Betamethasone valerate cream, ointment [prescribing information]. Parsippany, NJ: Actavis Pharma, Inc; November 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fougera.2">
<a name="Fougera.2"></a>Betamethasone valerate foam [prescribing information]. Melville, NY: Fougera; June 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ingenus.1">
<a name="Ingenus.1"></a>Betamethasone valerate foam [prescribing information]. Orlando, FL: Ingenus Pharmaceuticals, LLC; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Beteflam.1">
<a name="Beteflam.1"></a>Beteflam (betamethasone valerate) [product monograph]. Newmarket, Ontario, Canada: Progress Therapeutics Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.e1-10; quiz 427. doi: 10.1016/j.jaad.2013.09.009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-topical-pediatric-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28233354">
<a name="28233354"></a>Chi CC, Kirtschig G, Aberer W, et al. Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy. <i>J Eur Acad Dermatol Venereol</i>. 2017;31(5):761-773. doi: 10.1111/jdv.14101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-topical-pediatric-drug-information/abstract-text/28233354/pubmed" id="28233354" target="_blank">28233354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26497573">
<a name="26497573"></a>Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. <i>Cochrane Database Syst Rev</i>. 2015(10):CD007346. doi:10.1002/14651858.CD007346.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-topical-pediatric-drug-information/abstract-text/26497573/pubmed" id="26497573" target="_blank">26497573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DiproleneAF.1">
<a name="DiproleneAF.1"></a>Diprolene AF (betamethasone dipropionate) cream [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Diprolene.1">
<a name="Diprolene.1"></a>Diprolene (betamethasone dipropionate) lotion [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Diprolene.2">
<a name="Diprolene.2"></a>Diprolene (betamethasone dipropionate) ointment [prescribing information]. Jersey City, NJ: Organon LLC; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Diprolene.3">
<a name="Diprolene.3"></a>Diprolene (betamethasone dipropionate) [product monograph]. Kirkland, Quebec, Canada: Organon Canada Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Diprosone.1">
<a name="Diprosone.1"></a>Diprosone (betamethasone dipropionate) [product monograph]. Kirkland, Quebec, Canada: Organon Canada Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32738429">
<a name="32738429"></a>Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. <i>J Am Acad Dermatol</i>. 2021;84(2):432-470. doi:10.1016/j.jaad.2020.07.087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-topical-pediatric-drug-information/abstract-text/32738429/pubmed" id="32738429" target="_blank">32738429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16677965">
<a name="16677965"></a>Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. <i>Dermatol Clin.</i> 2006;24(2):167-97, vi. doi:10.1016/j.det.2006.01.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-topical-pediatric-drug-information/abstract-text/16677965/pubmed" id="16677965" target="_blank">16677965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Luxiq.1">
<a name="Luxiq.1"></a>Luxiq (betamethasone valerate foam) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; April 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Luxiq.2">
<a name="Luxiq.2"></a>Luxiq (betamethasone valerate) [Canadian product monograph]. Greenville, NC: Mayne Pharma Inc; March 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-topical-pediatric-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33108015">
<a name="33108015"></a>Oakley R, Arents BWM, Lawton S, Danby S, Surber C. Topical corticosteroid vehicle composition and implications for clinical practice. <i>Clin Exp Dermatol</i>. 2021;46(2):259-269. doi:10.1111/ced.14473<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-topical-pediatric-drug-information/abstract-text/33108015/pubmed" id="33108015" target="_blank">33108015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sernivo.1">
<a name="Sernivo.1"></a>Sernivo (betamethasone dipropionate spray) [prescribing information]. San Antonio, TX: DPT Laboratories, Ltd; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-topical-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33719380">
<a name="33719380"></a>Stacey SK, McEleney M. Topical corticosteroids: choice and application. <i>Am Fam Physician</i>. 2021;103(6):337-343.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-topical-pediatric-drug-information/abstract-text/33719380/pubmed" id="33719380" target="_blank">33719380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20027937">
<a name="20027937"></a>Tadicherla S, Ross K, Shenefelt PD, Fenske NA. Topical corticosteroids in dermatology. <i>J Drugs Dermatol</i>. 2009;8(12):1093-1105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-topical-pediatric-drug-information/abstract-text/20027937/pubmed" id="20027937" target="_blank">20027937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31231864">
<a name="31231864"></a>Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. <i>J Eur Acad Dermatol Venereol</i>. 2019;33(9):1644-1659. doi:10.1111/jdv.15709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/betamethasone-topical-pediatric-drug-information/abstract-text/31231864/pubmed" id="31231864" target="_blank">31231864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/.</div>
</li></ol></div><div id="topicVersionRevision">Topic 95149 Version 360.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
